2:26-cv-12589
Supernus Pharma Inc v. Ascent Pharma Inc
I. Executive Summary and Procedural Information
- Parties & Counsel:
- Plaintiff: Supernus Pharmaceuticals, Inc. (Delaware)
- Defendant: Ascent Pharmaceuticals, Inc. (New York); Camber Pharmaceuticals, Inc. (Delaware); and Hetero Labs Limited (India)
- Plaintiff’s Counsel: Saul Ewing LLP
- Case Identification: 2:26-cv-12589, D.N.J., 09/23/2026
- Venue Allegations: Plaintiff alleges venue is proper in the District of New Jersey based on Defendant Camber Pharmaceuticals, Inc.'s principal place of business in Piscataway, NJ, and Defendant Hetero Labs Limited's sole U.S. marketing office also being located in Piscataway, NJ. The complaint further alleges all defendants work as a unitary business and have purposefully directed activities toward the state, including the anticipated marketing and sale of the accused products.
- Core Dispute: Plaintiff alleges that Defendants' filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) to market generic viloxazine extended-release capsules constitutes an act of infringement of six U.S. patents related to Plaintiff's branded ADHD drug, Qelbree®.
- Technical Context: The technology concerns pharmaceutical formulations for extended-release delivery of viloxazine and methods of using viloxazine to treat Attention Deficit Hyperactivity Disorder (ADHD) and related conditions.
- Key Procedural History: This lawsuit was initiated under the Hatch-Waxman Act following Defendants’ submission of ANDA No. 221638 and a subsequent Paragraph IV certification notice letter sent to Supernus on or about August 13, 2026. The patents-in-suit are listed in the FDA’s Orange Book as covering Supernus’s Qelbree® product. The complaint notes that the matter in controversy involves the same plaintiff, drug product, and patents at issue in a previously filed case, In re Viloxazine, C.A. No. 2:25-cv-12183 (D.N.J.).
Case Timeline
| Date | Event |
|---|---|
| 2008-09-05 | Priority Date for '753, '143, '523 Patents |
| 2012-02-08 | Priority Date for '204, '853, '338 Patents |
| 2012 | Hetero forms Ascent Pharmaceuticals |
| 2016-06-07 | U.S. Patent No. 9,358,204 Issued |
| 2017-03-28 | U.S. Patent No. 9,603,853 Issued |
| 2017-05-30 | U.S. Patent No. 9,662,338 Issued |
| 2022-05-10 | U.S. Patent No. 11,324,753 Issued |
| 2022-10-04 | U.S. Patent No. 11,458,143 Issued |
| 2024-10-22 | U.S. Patent No. 12,121,523 Issued |
| 2026-08-13 | Defendants send Paragraph IV Notice Letter |
| 2026-09-23 | Complaint Filed |
II. Technology and Patent(s)-in-Suit Analysis
U.S. Patent No. 9,358,204 - Formulations of Viloxazine
The Invention Explained
- Problem Addressed: The patent’s background section states that viloxazine’s characteristics—including a potentially high therapeutic dose, weakly basic nature, and high in vivo clearance rate—present challenges for developing an extended-release formulation suitable for once or twice-daily administration ’204 Patent, col. 1:41-47
- The Patented Solution: The invention provides modified-release formulations of viloxazine that control the drug’s release over an extended period. This is achieved using compositions that may include an immediate-release component and an extended-release component, which can be formulated into various systems like matrix tablets or multiparticulates within a capsule ’204 Patent, col. 2:1-4 These formulations are designed to contain a release-rate controlling compound, such as a hydrophilic or hydrophobic polymer, to achieve a drug release profile lasting at least two hours ’204 Patent, col. 5:6-14 ’204 Patent, abstract
- Technical Importance: This technology enables less frequent dosing (e.g., once or twice daily) compared to traditional immediate-release versions, which can improve patient compliance and potentially reduce adverse side effects associated with rapid drug absorption ’204 Patent, col. 3:15-29
Key Claims at a Glance
- The complaint does not specify which claims are asserted, but reserves the right to assert one or more claims of the patent (’204 Patent, Compl. ¶80). Independent claim 1 is representative of the patent's formulation technology.
- The essential elements of independent claim 1 include:
- A pharmaceutical formulation comprising an immediate release (IR) component and an extended release (XR) component.
- The IR component includes an inert core and a layer with viloxazine.
- The XR component includes an inert core, a first layer with viloxazine, and a second layer with a release rate controlling compound and a pore former.
- The formulation comprises 25% to 75% (w/w) viloxazine.
- At least 80% of the viloxazine is released over at least 2 hours in vitro.
- The complaint reserves the right to assert additional claims, which may include dependent claims (’204 Patent, Compl. ¶80).
U.S. Patent No. 9,603,853 - Formulations of Viloxazine
The Invention Explained
- Problem Addressed: Similar to the ’204 patent, the ’853 patent addresses the challenges of formulating viloxazine for extended release, citing its potentially high therapeutic dose and rapid in vivo clearance ’853 Patent, col. 1:41-47
- The Patented Solution: The patent discloses modified-release pharmaceutical formulations that allow for controlled delivery of viloxazine. The invention describes specific compositions, such as a formulation containing an extended-release (XR) component with a release rate controlling compound, to achieve a desired pharmacokinetic profile suitable for less frequent administration ’853 Patent, col. 2:1-13 ’853 Patent, abstract
- Technical Importance: By providing a reliable extended-release mechanism, the invention facilitates a once or twice-daily dosing regimen, which is more convenient for patients and may improve treatment adherence and outcomes ’853 Patent, col. 3:25-34
Key Claims at a Glance
- The complaint does not specify which claims are asserted, but alleges infringement of one or more claims (’853 Patent, Compl. ¶101). Independent claim 1 is representative.
- The essential elements of independent claim 1 include:
- A pharmaceutical formulation comprising an extended release (XR) component.
- The XR component contains an inert core, a first layer with viloxazine, and a second layer with a release rate controlling compound and a pore former in a specific weight ratio.
- The formulation comprises 25% to 75% (w/w) viloxazine.
- At least 80% of the viloxazine is released over at least 2 hours in vitro.
- The complaint reserves the right to assert additional claims, which may include dependent claims (’853 Patent, Compl. ¶101).
U.S. Patent No. 9,662,338 - Formulations of Viloxazine
Technology Synopsis
The ’338 patent, like the '204 and '853 patents, is directed to solving the technical problems associated with creating a viable extended-release formulation of viloxazine, a drug with a high clearance rate ’338 Patent, col. 1:41-47 It discloses modified-release compositions, including those with both immediate-release and extended-release components, to provide therapeutic levels of the drug over a prolonged period with once or twice-daily dosing ’338 Patent, col. 2:1-13 ’338 Patent, abstract
Asserted Claims
The complaint does not specify which claims of the ’338 patent are asserted Compl. ¶122
Accused Features
The infringement allegation is based on Defendants' submission of ANDA No. 221638 seeking approval to market generic viloxazine extended-release capsules Compl. ¶120 Compl. ¶123
U.S. Patent No. 11,324,753 - Method of Treatment of Attention Deficit/Hyperactivity Disorder (ADHD)
Technology Synopsis
This patent claims a method of treating ADHD by administering viloxazine. The invention is based on the discovery that viloxazine exhibits antagonist activity at specific serotonin receptors (5-HT7 and 5-HT1B), a previously unknown mechanism of action relevant to ADHD treatment ’753 Patent, abstract ’753 Patent, col. 2:56-62
Asserted Claims
The complaint does not specify which claims of the ’753 patent are asserted Compl. ¶143
Accused Features
The infringement allegation is based on Defendants seeking FDA approval to market their generic product for the treatment of ADHD, with a proposed label that allegedly instructs and encourages physicians and patients to use the drug for this indication, thereby inducing infringement of the patented method Compl. ¶141 Compl. ¶152
U.S. Patent No. 11,458,143 - Method of Treatment of Attention Deficit/Hyperactivity Disorder (ADHD)
Technology Synopsis
This patent claims a method of treating a patient suffering from ADHD by administering a formulation of viloxazine or a salt thereof ’143 Patent, abstract ’143 Patent, claim 1 The invention is based on the discovery of viloxazine's antagonist activity at serotonin receptors 5-HT1B and/or 5-HT7, providing a novel therapeutic approach for ADHD ’143 Patent, col. 2:20-24 ’143 Patent, col. 2:56-62
Asserted Claims
The complaint does not specify which claims of the ’143 patent are asserted Compl. ¶164
Accused Features
Infringement is alleged based on Defendants seeking to market a viloxazine product specifically for the treatment of ADHD, with a proposed label that will induce infringement by end-users Compl. ¶162 Compl. ¶173
U.S. Patent No. 12,121,523 - Method of Treatment of Attention Deficit/Hyperactivity Disorder (ADHD)
Technology Synopsis
This patent claims a method of treating a patient for a mood or affective disorder (such as anxiety or depression) that is co-morbid with ADHD. The treatment consists of administering a therapeutically effective amount of viloxazine ’523 Patent, abstract ’523 Patent, claim 15
Asserted Claims
The complaint does not specify which claims of the ’523 patent are asserted Compl. ¶185
Accused Features
The infringement allegation is based on Defendants seeking to market a viloxazine product for ADHD with a proposed label that allegedly instructs patients to seek medical help for "new or worse depression" or "new or worse anxiety," which Plaintiff contends will induce infringement of the patented method of treating co-morbid disorders Compl. ¶74 Compl. ¶183 Compl. ¶194
III. The Accused Instrumentality
Product Identification
The accused products are Ascent Pharmaceuticals, Inc.’s viloxazine extended-release capsules in 100 mg, 150 mg, and 200 mg strengths ("Ascent's ANDA Products"), for which Defendants have filed ANDA No. 221638 with the FDA Compl. ¶11
Functionality and Market Context
The complaint alleges that Ascent's ANDA Products are generic versions of Supernus’s Qelbree® and are based on Qelbree® as the reference listed drug Compl. ¶65 The products are intended for the treatment of ADHD in adults and pediatric patients 6 years and older Compl. ¶70 The proposed prescribing information is alleged to contain specific dosage and administration instructions that mirror those of Qelbree®, as well as sections on the mechanism of action and pharmacodynamics Compl. ¶¶71-73 The defendants have allegedly represented to the FDA that their products are bioequivalent to Qelbree® Compl. ¶67 The filing of the ANDA itself is the statutory act of infringement that gives rise to this lawsuit under 35 U.S.C. § 271(e)(2) Compl. ¶84
No probative visual evidence provided in complaint.
IV. Analysis of Infringement Allegations
The complaint does not provide detailed infringement contentions or claim charts. The infringement allegations are based on the statutory act of infringement under 35 U.S.C. § 271(e)(2)(A), where the submission of an ANDA to obtain approval for a generic drug before patent expiration is an act of infringement. The following tables summarize the infringement theory for the lead formulation patents based on the complaint’s allegations.
9,358,204 Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| A pharmaceutical formulation, comprising: (a) an immediate release (IR) component... and (b) an extended release (XR) component... | Defendants submitted ANDA No. 221638 for "viloxazine extended-release capsules," which are alleged to be bioequivalent to the patented Qelbree® product. The existence of both immediate and extended release characteristics is implied by the product's nature as an extended-release capsule designed to match the reference drug's pharmacokinetic profile. | ¶78; ¶84; ¶67 | col. 2:1-4 |
| wherein the IR component comprises an inert core and a layer comprising viloxazine... surrounding the core | The ANDA Products are alleged to be extended-release capsules that are bioequivalent to Qelbree®. The complaint does not specify the internal structure, but this structure is a known method for creating multi-part release profiles in capsule formulations. | ¶67; ¶78 | col. 7:6-8 |
| wherein the XR component comprises: (i) an inert core, (ii) a first layer comprising viloxazine... and (iii) a second layer comprising a release rate controlling compound and a pore former... | As extended-release capsules bioequivalent to the Orange Book-listed product, the ANDA Products are alleged to necessarily contain the structural elements, including release-controlling excipients, claimed in the patent that covers the branded product. | ¶67; ¶78 | col. 7:31-40 |
| wherein the formulation comprises, as a percentage of the total formulation, 25% (w/w) to 75% (w/w) viloxazine | The ANDA products are for 100 mg, 150 mg, and 200 mg dosage strengths, consistent with commercial pharmaceutical formulations that would contain a substantial weight percentage of the active ingredient. | ¶66 | col. 2:7-9 |
9,603,853 Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| A pharmaceutical formulation, comprising: an extended release (XR) component... | Defendants submitted an ANDA for "viloxazine extended-release capsules." The infringement allegation is predicated on this filing and the assertion that the proposed generic product will infringe upon approval. | ¶99; ¶105 | col. 2:1-13 |
| wherein the XR component comprises: (i) an inert core, (ii) a first layer comprising viloxazine... and (iii) a second layer comprising a release rate controlling compound and a pore former... | The ANDA Products are alleged to be bioequivalent to Qelbree®. The complaint's theory is that to achieve bioequivalence with the patented product, the generic version must practice the claimed formulation structure, including its specific layered components and release-controlling agents. | ¶67; ¶99 | col. 7:31-40 |
| wherein the formulation comprises, as a percentage of the total formulation, 25% (w/w) to 75% (w/w) viloxazine | The proposed 100 mg, 150 mg, and 200 mg dosage strengths are consistent with formulations having a high drug load as claimed. | ¶66 | col. 2:7-9 |
- Identified Points of Contention:
- Scope Questions: A central question for the court will be the proper construction of key claim terms. For the formulation patents ('204, '853, and '338), the scope of terms like "release rate controlling compound" and "pore former" will be critical. For the method-of-use patents ('753, '143, and '523), a key issue will be whether the proposed product label is sufficient to prove inducement of infringement for the claimed methods, including the treatment of co-morbid disorders.
- Technical Questions: Since direct infringement in an ANDA case often hinges on whether the branded product itself practices the claims, a key technical question will be whether the specific formulation of Supernus's Qelbree® product embodies every element of the asserted independent claims. The primary defense in such cases is often a challenge to the validity of the patents, for instance, on grounds of obviousness over prior art related to extended-release technologies and viloxazine.
V. Key Claim Terms for Construction
The Term: "release rate controlling compound" (appears in claims of the '204 and '853 patents)
Context and Importance: The definition of this term is fundamental to the scope of the formulation patents. Practitioners may focus on this term because its breadth will be a central point of contention. A broad construction could render the claims vulnerable to invalidity challenges based on prior art extended-release excipients, while a narrow construction might allow Defendants to design around the claims or argue non-infringement.
Intrinsic Evidence for Interpretation:
- Evidence for a Broader Interpretation: The specification provides a long list of potential hydrophilic and hydrophobic compounds that can serve this function, suggesting the term is not limited to a specific class of polymer ’204 Patent, col. 5:18-54
- Evidence for a Narrower Interpretation: The specific examples in the patent use particular compounds (e.g., hypromellose, Surelease®, EUDRAGIT®) in specific ratios, which could be used to argue that the term should be limited to the types of compounds and systems actually demonstrated to work ’204 Patent, col. 12:28-18:67
The Term: "a method of treating a patient suffering from ADHD" (appears in claims of the '143 patent)
Context and Importance: This term defines the infringing act for the method-of-use patents. The dispute will likely center on what actions, particularly on the part of the generic manufacturer, constitute practicing this "method of treating." The core of the infringement allegation is that the proposed product label induces physicians to perform the claimed method.
Intrinsic Evidence for Interpretation:
- Evidence for a Broader Interpretation: The claim language itself is direct and does not appear to contain limiting words beyond the act of administering the drug to a patient with ADHD. The specification broadly discusses the utility of viloxazine for treating ADHD ’143 Patent, col. 2:20-31
- Evidence for a Narrower Interpretation: Defendants may argue that merely selling a drug with an indication for ADHD does not meet the legal standard for inducing the specific "method of treating." The patent's discussion of specific receptor antagonist activity (e.g., at 5-HT1B and 5-HT7 receptors) could be argued as an implicit limitation on the "method," raising the question of whether the proposed label must instruct or explain this specific mechanism to induce infringement ’143 Patent, col. 2:56-62
VI. Other Allegations
- Indirect Infringement: The complaint extensively pleads indirect infringement. For all six patents, it alleges that Defendants' proposed product labeling will actively induce infringement by instructing and encouraging physicians, pharmacists, and patients to prescribe, dispense, and use the ANDA Products in a manner that infringes the formulation and method claims Compl. ¶¶89-91 Compl. ¶¶111-112 Compl. ¶¶131-133 Compl. ¶¶152-154 Compl. ¶¶173-175 Compl. ¶¶194-196
- Willful Infringement: Willfulness is alleged based on Defendants’ pre-suit knowledge of the patents-in-suit. The complaint asserts that this knowledge is evidenced by Defendants' submission of an ANDA containing a Paragraph IV certification that specifically identified each of the asserted patents Compl. ¶94 Compl. ¶115 Compl. ¶136 Compl. ¶157 Compl. ¶178 Compl. ¶199
VII. Analyst’s Conclusion: Key Questions for the Case
- A core issue will be one of validity: Can Defendants prove by clear and convincing evidence that the asserted claims—covering specific extended-release formulations and methods of using viloxazine for ADHD—are invalid as obvious or anticipated by prior art, particularly given that viloxazine is a known compound?
- A second key issue will be one of inducement: For the method-of-use patents, does the language in the Defendants’ proposed product label meet the legal standard for inducing infringement? Specifically, does the label actively encourage or instruct physicians and patients to perform the patented methods, including the treatment of co-morbid mood disorders as claimed in the '523 patent?
- A final dispositive question will concern claim scope: Will the court adopt a broad or narrow construction of key formulation terms like "release rate controlling compound"? The outcome of claim construction will likely determine the strength of both Defendants' non-infringement arguments and their invalidity defenses.